Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600613's 5-Year Yield-on-Cost % is ranked worse than 62.96% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs SHSE:600613: 1.44
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shanghai Shenqi Pharmaceutical Investment Management Co 5-Year Yield-on-Cost % Related Terms
SHSE:600613 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Shanghai Shenqi Pharmaceutical Investment Management Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
Shanghai Shenqi Pharmaceutical Investment Management Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a 5-Year Yield-on-Cost % of 1.44 as of Jul. 30, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. This is 15% above median its historical median of 1.25. Over the past decade, Shanghai Shenqi Pharmaceutical Investment Management Co's 5-Year Yield-on-Cost % has ranged from 0.28 to 3.36. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #323 out of 513 companies in the Drug Manufacturers industry, placing it in the top 63%.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's 5-Year Yield-on-Cost % too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current 5-Year Yield-on-Cost % of 1.44 is 15% above median its 10-year median of 1.25. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 3.36. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 1.44 is 37.1% below this industry median. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #323 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #323 out of 513 companies for 5-Year Yield-on-Cost %. This places Shanghai Shenqi Pharmaceutical Investment Management Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 1.44 is 37.1% below this benchmark. Historically, Shanghai Shenqi Pharmaceutical Investment Management Co's own 5-Year Yield-on-Cost % has ranged from 0.28 to 3.36 over the past decade. While the company's 10-year median is 1.25 vs. the industry median of 2.29, Shanghai Shenqi Pharmaceutical Investment Management Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shenqi Pharmaceutical Investment Management Co's current 5-Year Yield-on-Cost % of 1.44 is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shenqi Pharmaceutical Investment Management Co's current 5-Year Yield-on-Cost % is 1.44, which is 15% above median its own 10-year median of 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.41, compared to a current price of ¥4.86 — trading 10.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.44, which is 15% above median its 10-year median of 1.25 and 37.1% below the Drug Manufacturers industry median of 2.29. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current 5-Year Yield-on-Cost % is 1.44 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥4.86 is trading 10.2% below its estimated GF Value™ of ¥5.41.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.
Key valuation signals for SHSE:600613:
5-Year Yield-on-Cost %: 1.44 (15% above median its 10-year median of 1.25)
GF Value™: ¥5.41 vs. price of ¥4.86 (10.2% below fair value)
Industry Position: 37.1% below the Drug Manufacturers median (#323 of 513)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
